open access
Avanafil — new drug for treatment of erectile dysfunction
open access
Abstract
Phosphodiesterase type 5 inhibitors are currently the first-choice drugs for treatment of erectile dysfunction. Avanafil is a novel phosphodiesterase type 5 inhibitor. The drug is characterized by the fast onset of action, higher selectivity, better efficacy and lower rates of side effects. It should be administered in dose of 50 mg to 200 mg. Avanafil is associated with more spontaneous sexual activity.
Abstract
Phosphodiesterase type 5 inhibitors are currently the first-choice drugs for treatment of erectile dysfunction. Avanafil is a novel phosphodiesterase type 5 inhibitor. The drug is characterized by the fast onset of action, higher selectivity, better efficacy and lower rates of side effects. It should be administered in dose of 50 mg to 200 mg. Avanafil is associated with more spontaneous sexual activity.
Keywords
avanafil, erectile dysfunction, phosphodiesterase type 5 inhibitors
About this articleTitle
Avanafil — new drug for treatment of erectile dysfunction
Journal
Seksuologia Polska (Polish Sexology)
Issue
Article type
Review paper
Bibliographic record
Seksuologia Polska 2013;11(2).
Keywords
avanafil
erectile dysfunction
phosphodiesterase type 5 inhibitors
Authors
Bartosz Puchalski
Filip M. Szymański